Blueprint Medicines Raises $40M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Start-up Blueprint Medicines today announced it has closed on a $40 million Series A round.

The round was led by Third Rock Ventures, and proceeds will be used to develop new cancer therapies using Blueprint's proprietary compound library and Insights-to-Validation platform that targets molecular drivers of cancer "and emerging resistance mechanisms unique to certain cancer patients," the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.